[go: up one dir, main page]

AR120884A1 - Anticuerpos anti-fgfr2b - Google Patents

Anticuerpos anti-fgfr2b

Info

Publication number
AR120884A1
AR120884A1 ARP200103629A ARP200103629A AR120884A1 AR 120884 A1 AR120884 A1 AR 120884A1 AR P200103629 A ARP200103629 A AR P200103629A AR P200103629 A ARP200103629 A AR P200103629A AR 120884 A1 AR120884 A1 AR 120884A1
Authority
AR
Argentina
Prior art keywords
fgfr2b
antibodies
fgfr2b antibodies
antigen
present disclosure
Prior art date
Application number
ARP200103629A
Other languages
English (en)
Inventor
Mei Wang
Qiuli Guo
Yu Bai
Zhenfan Yang
Xiaolin Zhang
Original Assignee
Dizal Jiangsu Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dizal Jiangsu Pharmaceutical Co Ltd filed Critical Dizal Jiangsu Pharmaceutical Co Ltd
Publication of AR120884A1 publication Critical patent/AR120884A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/461—Igs containing Ig-regions, -domains or -residues form different species
    • C07K16/464—Igs containing CDR-residues from one specie grafted between FR-residues from another
    • C07K16/465—Igs containing CDR-residues from one specie grafted between FR-residues from another with additional modified FR-residues
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/575—
    • G01N33/5758—
    • G01N33/5759—
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
    • C12N2015/8518—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic expressing industrially exogenous proteins, e.g. for pharmaceutical use, human insulin, blood factors, immunoglobulins, pseudoparticles
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/71—Assays involving receptors, cell surface antigens or cell surface determinants for growth factors; for growth regulators

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente divulgación proporciona anticuerpos anti-FGFR2b o fragmentos de unión a antígenos de estos, polinucleótidos aislados que codifican los mismos, composiciones farmacéuticas que los comprenden y los usos de estos.
ARP200103629A 2019-12-24 2020-12-23 Anticuerpos anti-fgfr2b AR120884A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN2019127903 2019-12-24

Publications (1)

Publication Number Publication Date
AR120884A1 true AR120884A1 (es) 2022-03-23

Family

ID=76573701

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP200103629A AR120884A1 (es) 2019-12-24 2020-12-23 Anticuerpos anti-fgfr2b

Country Status (11)

Country Link
US (1) US20230052256A1 (es)
EP (1) EP4081539A4 (es)
JP (1) JP7686000B2 (es)
KR (1) KR20220119143A (es)
CN (1) CN114901687A (es)
AR (1) AR120884A1 (es)
AU (1) AU2020410863A1 (es)
CA (1) CA3160811A1 (es)
MX (1) MX2022007960A (es)
TW (1) TWI861325B (es)
WO (1) WO2021129656A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117917435A (zh) * 2022-10-21 2024-04-23 北京天广实生物技术股份有限公司 结合fgfr2b的抗体及其用途
CN121039158A (zh) * 2023-03-31 2025-11-28 杭州中美华东制药有限公司 新型抗fgfr2抗体
AU2024277592A1 (en) * 2023-05-19 2025-11-20 Sunshine Lake Pharma Co., Ltd. Anti-fgfr2 antibody and use thereof
US20250222125A1 (en) * 2024-01-05 2025-07-10 Beigene, Ltd. Anti-FGFR2b Antibodies, Conjugates and Methods of Use

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1012259E (pt) * 1997-06-04 2009-11-06 Oxford Biomedica Ltd Vector dirigido a tumor
KR20050119120A (ko) * 2003-03-14 2005-12-20 와이어쓰 인간 ⅰｌ-21 수용체에 대한 항체 및 그것의 용도
AU2003271174A1 (en) * 2003-10-10 2005-04-27 Chugai Seiyaku Kabushiki Kaisha Double specific antibodies substituting for functional protein
PT1680140E (pt) * 2003-10-16 2011-05-31 Imclone Llc Inibidores do receptor-1 do factor de crescimento de fibroblastos e m?todos de tratamento destes
US7371825B2 (en) * 2004-06-30 2008-05-13 Centocor, Inc. Anti-MCP-1 antibodies, compositions, methods and uses
EP2046384A4 (en) * 2006-06-15 2009-12-02 Fibron Ltd ANTIBODIES BLOCKING FIBROBLAST GROWTH FACTOR RECEPTOR ACTIVATION AND METHODS OF USING THE SAME
ES2646168T3 (es) * 2008-11-07 2017-12-12 Galaxy Biotech, Llc Anticuerpos monoclonales para el receptor del factor de crecimiento de fibroblastos 2
RU2014109038A (ru) * 2011-08-23 2015-09-27 Рош Гликарт Аг Антитела к хондроитинсульфат протеогликану меланомы
AR088941A1 (es) * 2011-11-23 2014-07-16 Bayer Ip Gmbh Anticuerpos anti-fgfr2 y sus usos
CA2859255A1 (en) * 2011-12-14 2013-06-20 Seattle Genetics, Inc. New antibody drug conjugates (adcs) and the use thereof
PE20210949A1 (es) * 2013-08-01 2021-05-24 Five Prime Therapeutics Inc Anticuerpos anti-fgfr2iiib afucosilados
KR20170080675A (ko) * 2014-11-05 2017-07-10 제넨테크, 인크. 항-fgfr2/3 항체 및 이의 이용 방법
TWI791422B (zh) * 2015-11-23 2023-02-11 美商戊瑞治療有限公司 用於癌症治療之單獨fgfr2抑制劑或與免疫刺激劑組合
MY197345A (en) * 2015-11-25 2023-06-14 Visterra Inc Antibody molecules to april and uses thereof
EP3544998A1 (en) * 2016-11-22 2019-10-02 Merck Patent GmbH Monoclonal antibody directed to fgfr1
WO2018095932A1 (en) * 2016-11-22 2018-05-31 Merck Patent Gmbh Monoclonal antibody directed to fgfr1
JP7692419B2 (ja) * 2019-12-24 2025-06-13 ディザル（ジァンスー）ファーマシューティカル・カンパニー・リミテッド 新規抗ＦＧＦＲ２ｂ抗体
CA3160810A1 (en) * 2019-12-24 2021-07-01 Dizal (Jiangsu) Pharmaceutical Co., Ltd. Novel anti-fgfr2b antibodies

Also Published As

Publication number Publication date
EP4081539A1 (en) 2022-11-02
TW202136310A (zh) 2021-10-01
EP4081539A4 (en) 2024-02-21
AU2020410863A1 (en) 2022-06-23
JP2023508173A (ja) 2023-03-01
US20230052256A1 (en) 2023-02-16
CA3160811A1 (en) 2021-07-01
TWI861325B (zh) 2024-11-11
MX2022007960A (es) 2022-07-12
JP7686000B2 (ja) 2025-05-30
WO2021129656A1 (en) 2021-07-01
KR20220119143A (ko) 2022-08-26
CN114901687A (zh) 2022-08-12

Similar Documents

Publication Publication Date Title
AR120883A1 (es) Anticuerpos anti-fgfr2b
AR120886A1 (es) Anticuerpos anti-fgfr2b
MX2022002111A (es) Novedosos anticuerpos anti-cldn18.2.
CO2021001893A2 (es) Anticuerpos anti-gdf15, composiciones y métodos de uso
UY40829A (es) Anticuerpos anti-phf-tau y sus usos
MX2020003093A (es) Anticuerpos anti-cd19 novedosos.
AR120884A1 (es) Anticuerpos anti-fgfr2b
ECSP19050049A (es) Anticuerpos anti-ox40 y sus usos
UY39798A (es) Anticuerpos anti-ccr8 y usos de los mismos
CO2018011364A2 (es) Anticuerpos anti-il-33, composiciones, métodos y usos de los mismos
CO2022008662A2 (es) Degradadores de smarca y usos de los mismos
ECSP18033227A (es) Anticuerpos agonistas que se unen específicamente a CD40 humana y métodos de uso
CO2018005614A2 (es) Anticuerpos que se unen específicamente a pd-1 y sus usos
MX2022015258A (es) Anticuerpos anti-cxcr5 y composiciones y usos de los mismos.
MX2017003359A (es) Inhibidores de proteina cinasa 2 activada por proteina cinasa activada por mitogeno (mk2) y sus usos.
MX2024010955A (es) Nuevos anticuerpos anti-cd3 y usos de los mismos
CR20160593A (es) Anticuerpos antagonistas del interferon alfa y omega
MX2022014896A (es) Anticuerpos anti-cldn18.2 y usos para diagnostico de los mismos.
CO2023000557A2 (es) Anticuerpos y métodos para tratar enfermedades asociadas a claudina
BR112022012731A2 (pt) Anticorpo anti-ox40 e uso do mesmo
CO2018012497A2 (es) Anticuerpos de interferón beta y usos de los mismos
MX2023008423A (es) Anticuerpos anti-gremlin1 novedosos.
MX2021008216A (es) Anticuerpos anti-tigit.
BR112021014944A2 (pt) Toxinas apxia, apxiia e apxiiia inativas
CL2025000292A1 (es) Anticuerpos tmem219 y usos terapéuticos de los mismos